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Abstract
The growing prevalence of antimicrobial resistance in major pathogens is outpacing discovery of new antimicrobial classes.
Vaccines mitigate the effect of antimicrobial resistance by reducing the need for treatment, but vaccines for many drug-
resistant pathogens remain undiscovered or have limited efficacy, in part because some vaccines selectively favor pathogen
strains that escape vaccine-induced immunity. A strain with even a modest advantage in vaccinated hosts can have high
fitness in a population with high vaccine coverage, which can offset a strong selection pressure such as antimicrobial use
that occurs in a small fraction of hosts. We propose a strategy to target vaccines against drug-resistant pathogens, by using
resistance-conferring proteins as antigens in multicomponent vaccines. Resistance determinants may be weakly
immunogenic, offering only modest specific protection against resistant strains. Therefore, we assess here how varying
the specific efficacy of the vaccine against resistant strains would affect the proportion of drug-resistant vs. –sensitive strains
population-wide for three pathogens – Streptococcus pneumoniae, Staphylococcus aureus, and influenza virus – in which
drug resistance is a problem. Notably, if such vaccines confer even slightly higher protection (additional efficacy between
1% and 8%) against resistant variants than sensitive ones, they may be an effective tool in controlling the rise of resistant
strains, given current levels of use for many antimicrobial agents. We show that the population-wide impact of such
vaccines depends on the additional effect on resistant strains and on the overall effect (against all strains). Resistance-
conferring accessory gene products or resistant alleles of essential genes could be valuable as components of vaccines even
if their specific protective effect is weak.
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Introduction
Increasing antimicrobial resistance in pathogen populations
results from concurrent selective processes [1]: emergence of
resistant strains in treated hosts and the differential transmission
success of resistant and sensitive strains. The latter effect becomes
increasingly important as the prevalence of resistant strains grows
[2]. Selection for resistance is often counteracted in untreated
hosts by a fitness cost of resistance: reduced viability, infectious-
ness, replication, or transmissibility of resistant strains relative to
sensitive ones [3]. Simple models for the spread of resistance in
populations suggest that the prevalence of resistance will increase
when selection for resistance by antimicrobial use outweighs the
fitness cost, and will decline otherwise [4,5]. A corollary of this
prediction is that, if both antimicrobial use and fitness cost remain
constant, then resistance prevalence should either remain near
zero (as in the case of penicillin resistance for Group A
Streptococcus [6] or, in some countries, fluoroquinolone resistance
in Streptococcus pneumoniae [7], or increase to approach 100% with
time, as has been the case in some pathogens (e.g. penicillin
resistance in Staphylococcus aureus [8], adamantane resistance in
influenza A/H3N2 [9] and oseltamivir resistance in influenza A/
H1N1 before 2009 [10]). In other pathogens, these scenarios do
not hold: the prevalence of resistance appears to stabilize at
intermediate values (e.g. resistance to several antimicrobial classes
in Streptococcus pneumoniae [11] or Neisseria gonorrhoeae [12]); more
complex models are required to explain such coexistence [11].
Vaccines are a key tool in the fight against resistant pathogens.
Some vaccines (e.g. diphtheria vaccine) can eliminate their
targeted disease in a population (via direct and herd-immunity
effects) and thereby obviate the need for treatment and concern
about resistance. Other vaccines, such as current vaccines against
pneumococcal disease and influenza, cannot eliminate transmis-
sion because their uptake or efficacy against colonization/infection
are too low, and/or because they do not cover all strains of their
target pathogen. By reducing disease burden, they nonetheless
reduce the need for treatment [13] and may thereby reduce the
selective pressure for resistance. Moreover, they reduce the impact
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of resistance, since fewer cases treated means fewer instances in
which treatment can fail due to resistance. Intriguingly, pneumo-
coccal conjugate vaccination had another benefit: the incidence of
drug-resistant infection declined disproportionately because the
pneumococcal serotypes in the vaccine tended to be more drug-
resistant than those excluded from the vaccine [14]. Unfortunate-
ly, as resistance has grown in non-vaccine types, this benefit has
waned, so that resistance prevalence is returning to pre-vaccine
levels [14,15], although total disease burden has declined.
If this feature of the pneumococcal conjugate vaccine –
disproportionate efficacy against drug-resistant strains of a
pathogen – could be made a permanent feature of pneumococcal
or other vaccines, then these vaccines could be a tool to increase
the fitness cost of resistance and possibly tip the balance between
antimicrobial selection and fitness cost in favor of the drug-
sensitive strains. Pathogen moieties conferring drug resistance have
not been popular targets for vaccines, perhaps because many drug
resistance determinants are poorly accessible to antibodies.
However, some important resistance determinants could be targets
of vaccination. Penicillin binding protein 2 (PBP2) of Neisseria
meningitidis is immunogenic and protective in a mouse model [16].
Whole-virus influenza vaccines induce immune responses to
neuraminidase [17], the target of oseltamivir and other neur-
aminidase inhibitors, which is altered in oseltamivir-resistant
strains [10]. Porins or efflux pumps that are altered (or uniquely
present) on the surface of resistant strains [18,19,20,21] might be
accessible to antibodies or elicit T cell responses. Certain efflux
pumps of Mycobacterium tuberculosis appear to contain T cell epitopes
[22] and vaccines that protect by inducing T cells [23,24] might be
capable of targeting even intracellular resistance-determining
moieties, such as antibiotic-modifying or target-modifying en-
zymes. Given the often-subtle genetic changes encoding resistance
in targets such as PBP2 or neuraminidase, immunity induced by
vaccination with a resistant allele of these determinants might be
only modestly more effective against resistant variants than against
sensitive variants. Yet a strain with even a modest advantage in
vaccinated hosts can have high fitness in a population with high
vaccine coverage, because the advantage will be realized in a high
proportion of hosts. In contrast, the selective effect of antimicrobial
use is to exert lethal selection against drug-sensitive strains in the
subset of infections that are treated, but this selection is felt in
relatively few hosts for organisms that are often carried asymp-
tomatically or that cause self-limiting infections.
The concept of using ecological approaches for eliminating drug
resistance (i.e. interventions designed to decrease the proportion of
drug-resistant strains in favor of drug-sensitive ones) has been
previously discussed [25], though this is still an underdeveloped
area of research. Traditional interventions to combat drug-
resistance involve infection control, which may be disproportion-
ately effective against resistant strains [26], killing drug-resistant
pathogens with new antimicrobial therapeutics, and preventing
the emergence of drug resistance in patients through the
administration of combination therapies, respectively. Ecological
approaches to combat drug resistance have been proposed less
frequently, including the use of vaccines or bacteriophages that
target specific antigens of the most transmissible and/or drug-
resistant clones [25].
Mathematical models have been used to study vaccine-induced
strain replacement as it relates to drug resistance in two studies (in
pneumococcus [27] and recently in S. aureus in hospital outbreaks
[28]). In the former, the authors model wide-scale childhood
immunization with a pneumococcal conjugate vaccine targeting
drug-resistant serotypes. The model successfully predicts a
transient reduction in drug-resistance population-wide that is not
sustained long term [27], as has also been observed in
epidemiological studies [14,15]. The explanation for this phenom-
enon is the increase in the rate of carriage of non-vaccine serotypes
among vaccinated individuals (serotype replacement) paired with
the increase in drug-resistance among these non-vaccine serotypes,
a phenomenon that does appear to be underway in the US [29].
Thus, the authors argue that targeting drug-resistant strains for
vaccination will not achieve a sustained reduction in drug-
resistance. In a second modeling study, the authors model
hospital-based immunization with a vaccine targeting a resistant
strain of S. aureus. The model predicts the elimination of drug-
resistance in a closed hospital setting, but in an open hospital
setting with a constant flow of newly admitted patients, drug-
resistance is shown to remain constant despite immunization [28].
This observation is explained by the lag time required to induce
protective immunity following vaccination, compared with the
influx of new non-vaccinated patients.
Previous models do not clearly support a role for vaccinating
against drug-resistant strains in achieving sustainable population-
wide reductions in drug-resistance. Thus here we model vaccina-
tion against resistance-conferring proteins themselves, such that
reduction of vaccine-targeted strains remains permanently linked
to those strains containing drug-resistance determinants. We
model this situation in a wide-scale vaccination scenario in order
to test the effectiveness of such vaccination population-wide, and
model conditions for three diverse microbes. Specifically, we test
the possibility that modest differential effectiveness due to
vaccination with resistance determinants could lead to substantial
selective pressure at the population level, sufficient to offset
realistic levels of selection from antimicrobial use.
Materials and Methods
For the pnemococcal vaccine model, we employed a suscepti-
ble-infectious-susceptible (SIS) model that allows individuals to be
colonized with both drug-sensitive and -resistant strains and
permits coexistence of both strains. Drug-resistant strains start out
as a minority of all strains (consistent with penicillin-resistance
prevalence of 24% in the U.S.) [30], in the presence of high levels
of antibiotic usage (consistent with that of young children in the
U.S.) [31], and in the presence of a vaccine with additional efficacy
against drug resistance determinants. We assumed 80% coverage
of the vaccine in the segment of the population responsible for
most transmission, as would be realized after 4–5 years of infant
vaccination if the core group were children under 5 [14,32].
For the staphylococcal vaccine, we used an SIS model in which
individuals can be colonized by either a drug-sensitive or a drug-
resistant strain, but not both. We modeled the rate of treatment
that clears MSSA (but not MRSA) in the community as 50% of
the MSSA-specific antibiotic prescriptions in the U.S [33], to
account for the fact that not all antimicrobial treatment clears
carriage, and modeled fitness costs within the range previously
measured for methicillin-resistant S. aureus [34]. The system of
differential equations has four equilibrium states (i. sensitive strain
reaches 100%, ii. resistant strain reaches 100%, iii. coexistence
and iv. elimination of both strains); we identified stability
conditions using eigenvalues of the Jacobian matrix (see Support-
ing Information). We assessed a range of parameter values
required to eliminate resistance by plotting equilibrium stability
conditions as a function of resistant strain-specific vaccine efficacy
(VER) and vaccine coverage (p) and for multiple different fitness
costs within the range previously measured for MRSA [34].
For the influenza vaccine, the model structure and parameter
values were taken from Ref. [2] except that 30% of the population
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(all ages) was assumed immune due to prior exposure at the start of
the season, a fraction p of the population were vaccinated at the
start of the season, and the vaccine was 59% effective [35] against
infection with the drug-sensitive virus, with an additional efficacy h
against resistant infection.
The systems of equations for each model are provided in the
Supporting Information, and parameter values are provided in
Table 1.
Results
To assess the impact of a resistance targeting vaccine on an
endemic, colonizing pathogen in which resistant strains currently
coexist with drug-sensitive strains, we considered the example of a
pneumococcal vaccine that preferentially immunizes against
penicillin-resistant variants, based on a structurally neutral co-
colonization model of strain coexistence [11] (Figure 1A). We
evaluated the model’s equilibrium state across a range of values for
overall vaccine efficacy (VE) and the increase in vaccine efficacy
against the resistant strain (h). By varying VE and h, we identified
conditions under which (i) drug-resistance reaches 100%, (ii) drug-
sensitivity reaches 100%, (iii) co-existence of drug-resistant and -
sensitive strains occurs, or (iv) both strains are eliminated. If there
was no fitness cost to resistance, drug-resistance would reach 100%
at baseline and between 7 and 13% additional resistant-strain-
specific vaccine efficacy against the drug-resistant strain would be
required to eliminate it (Figure 1B). However, a fitness cost of
resistance (which has been shown to occur for penicillin resistance
in pneumococci [36] and for many other resistance mechanisms in
diverse microbes [37]) partially offsets the effect of high antibiotic
usage, resulting in the coexistence of resistant and sensitive strains
at baseline, as presently observed for penicillin resistance in S.
pneumoniae [11]. Here, as additional vaccine efficacy against the
drug-resistant strain (h) increases, drug resistance eventually
disappears, outcompeted by the sensitive strain (Figure 1C). We
find that for drug resistance to be eliminated, the vaccine needs
only an additional 1–4% resistant strain-specific vaccine efficacy,
given overall VE of up to 40% against all pneumococci.
Next, we considered a pathogen for which no vaccine currently
exists, and for which the introduction of a drug-resistance-
targeting vaccine could occur in the absence of a general acting
vaccine for that pathogen. Community-associated (CA) Staphylo-
coccus aureus is an endemic colonizing pathogen with high
prevalence (carriage in 14 to 36% of healthy study cohorts) and
rising rates of methicillin resistance (5% to 45% of carriers)
[38,39,40,41,42]. Here we used a simpler single strain colonization
model (Figure 2A) in which the vaccine exerts an effect against
drug-resistant (methicillin-resistant S. aureus, MRSA) strains only,
with no vaccine effect on drug-sensitive (methicillin-susceptible S.
aureus, MSSA) strains. To test multiple vaccine mechanisms, we
modeled either a reduced risk of acquisition (Figure 2B), or
accelerated clearance rate upon getting colonized (Figure S1). We
determined conditions for the stability of each equilibrium state
and found that resistant strains are specifically eliminated when
p:VERw1{
u(1zy)
tzu
, where p is vaccine coverage, VER is
MRSA-specific vaccine efficacy, t is the rate at which treatment
clears colonization of MSSA, 1=u is the mean duration of
colonization in untreated hosts, and y is the fitness cost of
resistance. Thus drug-resistance is eliminated when the overall
effect of the vaccine against MRSA (coverage6efficacy) is greater
than the overall benefit of drug resistance, given as 1 minus the
ratio of MRSA clearance rate to MSSA clearance rate. We
assessed a range of vaccine efficacies (VER) and coverage (p)
required to eliminate resistance and found that if the vaccine had
high coverage (80%), only a marginal vaccine effect (0.6–7.5%)
would be required to eliminate drug-resistance (Figure 2B). These
modest MRSA-specific vaccine effects are in the same range as the
1–7% fitness costs that are believed to have led to a reduction of
MRSA in Denmark following reduced antibiotic usage [34]. A
variety of mechanisms lead to resistance in S. aureus (drug-
inactivating enzymes, mutated PBP/target site and high expres-
sion of efflux pumps [20]), and depending on antigenicity and
Table 1. Parameter Values.
Symbol Description S. pneumo value S. aureus value Flu value
b Transmission rate/week 0.4167 (based on 30–50%
prevalence [58])
0.0893 (based on 30%
prevalence [41])
Varies by age, see [2]
t Treatment rate/week 0.02 (lower end of childhood
antibiotic prescribing range [59])
0.0003, 0.0017, 0.0033
(10, 50, and 100% respectively of
MSSA-active antibiotic prescriptions
per person per week in the U.S.,
weighted by ages in 2010 census
data [33])
40% of infections are treated
u Clearance rate/week 0.25 (duration of 30 days
[60,61])
0.01, 0.02, 0.04
(duration of 175–700 days [56,57])
2.1 (duration of 3.3 days)
p Proportion of population
that is vaccinated
0.8 (well below U.S. childhood
vaccination rates [62])
Range: 0–1 0.4
VE Vaccine efficacy (overall) Range: 0–1 n/a 59% (effects on infectiousness
neglected)
h or VER Additional vaccine efficacy
against resistant strain (h, S.
pneumo, Flu) or total vaccine
efficacy against resistant strain
only (VER, S. aureus)
Range: 0–1 Range: 0–1 Range: 0–20%
y Fitness cost Range: 0, 0.08 (estimated
based on in vitro data [36])
0.02, 0.04, 0.08 (range of
fitness costs in field strains [34])
0
doi:10.1371/journal.pone.0068940.t001
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distribution in MRSA and MSSA clones, could serve as potential
candidates for such a vaccine. Indeed, even if methicillin resistance
itself could not be effectively targeted, there would be therapeutic
benefit in maintaining the susceptibility of S. aureus to alternative
drugs, as was initially the case with most CA-MRSA [43].
Alternatively or in addition, partially effective immunization could
be achieved against factors associated with successful CA-MRSA
clones, such as various staphylococcal toxins [44] which may even
be genetically linked to methicillin resistance [45]; a caveat (see
Discussion) to targeting linked factors rather than resistance
determinants themselves is that these linkages might not persist
once selection by the vaccine is in place, and the effect on
resistance might be transient. High coverage rates could be
achieved by combining this vaccine with a routinely given
childhood vaccine.
Last, we considered deployment of a killed influenza vaccine
that includes a drug-resistant version of the neuraminidase (as a
supplement to the hemagglutinin that forms the majority of
antigenic material in current vaccines). We modeled a scenario
(analogous to that at the end of the 2007–8 influenza season in
some countries) in which a transmissible strain resistant to a
neuraminidase inhibitor has been identified but has not yet
reached fixation in a particular population (Figure 3A). A vaccine
incorporating this resistant neuraminidase, we assumed, offers
marginally greater protection against resistant infection than
against infection with a drug-sensitive strain. We assumed that
10% of the cases that seeded the epidemic at the start of the season
were resistant (due to importation) and as a worst-case scenario
that resistance had no intrinsic fitness cost. We found that a
vaccine of 7% increased efficacy against the resistant strain (66%
Figure 1. Modeling a vaccine with increased efficacy against drug-resistance determinants for an endemic colonizing pathogen (S.
pneumoniae). a, SIS model with a proportion p of the population vaccinated and initially susceptible (Y ) and 1{p unvaccinated and initially
susceptible (X ), who can get infected with either the drug-sensitive strain (S subscript), –resistant strain (R subscript), or both (SR subscript) strains.
Plots depict model state at equilibrium (all drug-resistant, all drug-sensitive, stable co-existence of both strains, or elimination of all strains) across a
range of overall vaccine efficacy (VE) and additional vaccine efficacy against resistant strain (h), where vaccine coverage is 80%. Plots show situation
with no fitness cost (b) and with 8% fitness cost (c). Color scheme throughout the paper is as follows: uninfected (gray), sensitive (blue), resistant
(red), co-infected with both strains/coexistence of both strains (purple). This model corresponds to Model E of Ref [11].
doi:10.1371/journal.pone.0068940.g001
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efficacy vs. 59% against the sensitive strain) could counteract the
effect of treating approximately 10% of the population with
oseltamivir (Figure 3B). In 2007, the spread of oseltamivir
resistance may have been mainly due to the appearance of a
fitness benefit associated with the resistant strain, even in the
absence of treatment [46], rather than by antiviral use. A
resistance vaccine could also slow the spread of resistant virus in
such a scenario (Figure S3).
Discussion
Vaccines targeting drug-resistant determinants can have a
substantial impact at the population level by reducing the
competitive advantage held by these microbes due to the selective
effect of drug pressure. These simplified models abstract away
important features of transmission in each pathogen, including
strain-specific immunity, host heterogeneity, and transmission
between countries that might have different vaccination policies;
thus precise predictions of the quantitative effects of such vaccines
would depend on more detailed models of both pathogen
transmission and vaccine effect. Nonetheless, with varying
structures and assumptions, these models show that with high
coverage, a vaccine with extremely modest effects (well below
those typically sought for vaccines) could retard the spread of drug
resistance in a range of pathogens.
The benefit of a resistance vaccine depends on specific increased
efficacy against the resistant type. Recent work on Th17-based
immunity to pneumococci shows that antigen-specific immunity
elicited in the setting of dual carriage of antigen-bearing and
antigen-lacking pneumococci leads to near-equal clearance of both
strains, because the activation (via T cells) but not the effector cells
(neutrophils) are antigen-specific [47]. Such a vaccine would have
lower effectiveness in suppressing resistance because its additional
effect against the resistant strain would be realized in hosts
colonized with only the sensitive or resistant strain, but not in hosts
co-colonized with both. Vaccines based on antibodies, CD8+ T
cells, or other mechanisms that target effectors to antigen-positive
cells would not have this limitation.
The amount of resistance-specific efficacy required to eliminate
drug-resistance depends on a range of parameters relating to the
biology of the pathogen (duration of colonization, fitness cost of
drug-resistance), the degree to which interventions are used
Figure 2. Modeling a vaccine against drug-resistance determinants for an endemic colonizing pathogen for which no vaccine
currently exists (S. aureus). a, SIS model with a proportion p of the population as vaccinated susceptibles (Y ) and 1{p as unvaccinated
susceptibles (X ), who can get colonized with either the drug-sensitive (S subscript), or –resistant (R subscript) strain. b, Contour plot of equilibrium
stability conditions as a function of vaccine coverage (p) and specific vaccine efficacy against resistant strain (VER), for 3 fitness costs. Stability
conditions for the resistant-only and sensitive-only equilibrium were obtained analytically and were mutually exclusive. The stable equilibrium state is
plotted by color as a function of fitness cost (different panels), vaccine efficacy against the resistant strain (x-axis) and vaccine coverage (y-axis).
doi:10.1371/journal.pone.0068940.g002
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(treatment rate, vaccine coverage), and the overall efficacy of
vaccination against all strains. For each of the organisms we
modeled, modest vaccine efficacies were required to eliminate
resistance. Despite differences in parameter values (Table 1) and
overall vaccine efficacy (ranging between 0–59%), we predict that
between 1–13% resistance-specific efficacy is required to eliminate
resistance in each system, given an 80% vaccination coverage rate.
As treatment rate and duration of infection are not well
understood for S. aureus, we tested a range of parameter values
to encompass the range reported in the literature (Table S1 in File
S1). Higher resistance-specific vaccine efficacies were required to
eliminate resistance when treatment rates or durations of
colonization increased, or fitness costs were reduced (Figure S2
and Table S1 in File S1). However, across the entire range of
parameters tested, the resistant-specific efficacy required to
eliminate drug-resistance never surpassed 30%. While additional
research into these parameter values could help the model’s
accuracy, the overall result still suggests a modestly effective
vaccine is capable of eliminating drug-resistance if given at high
coverage.
Comparing our results with those from prior modeling studies
on using vaccination to target drug-resistance, we are the first to
show that targeting of drug-resistance determinants can lead to
sustained reduction in drug-resistance population-wide. Vaccina-
tion with resistance determinants themselves would slow, if not
prevent, the process by which resistance determinants spread in
strains where the vaccine-targeted antigens are absent, as modeled
in Temime et al [27] and happened within several years of
pneumococcal conjugate vaccination in the US [14,29]. We
predict that 1–13% resistant-specific vaccine efficacy is required
for eliminating drug resistance, which is substantially lower than
that shown in Tekle et al, in which 56–83% resistance-specific
vaccine efficacy was required to eliminate drug-resistance in
hospital settings [28]. This difference could be explained due to
our focus on vaccination in the community. Vaccination in the
community is a more attractive option for reducing drug-resistance
population-wide than vaccination prior to hospital admission
because (1) vaccines against colonizing organisms generally
prevent colonization better than they induce clearance of
colonization once established [48]; and (2) durations of hospital
stays, which average about 5 days in the US [49] are shorter than
the typical time required for vaccination to elicit protective
immunity (weeks).
One caveat of our approach is that drug-resistance in a single
organism can arise through a variety of mechanisms and thus
drug-resistance conferring proteins, meaning that if vaccines target
only one drug-resistance conferring protein, microbes expressing
alternate proteins that confer resistance could spread in the
population. In several of the organisms we explore, multiple
mechanisms and proteins are involved in conferring drug-
resistance. For this intervention to succeed, drug-resistance
vaccines should only be used for organisms in which vaccines
can be generated against epitopes covering the range of resistance-
conferring proteins for that organism. Alternatively, they could be
designed for organisms with only one known resistance-conferring
mechanism.
Current methods for combating drug-resistance include the
development of new drugs to kill drug-resistant microbes, and new
drug combinations to prevent de novo evolution of drug-resistance.
Microbes have been shown to acquire drug-resistance at alarming
rates, which requires the continuous development of new
antimicrobials in order to keep up with this arms race. While
high throughput drug discovery programs are useful in this
process, getting new drugs approved is a long and expensive
process. Further, there are no guarantees that we can keep up, as
evidenced by the virtually untreatable forms of extensively drug
resistant tuberculosis (XDR-TB) that have cropped up in recent
years. Thus, the use of ecological-focused interventions that
attempt to steer microbial populations toward drug-sensitive
infections rather than drug-resistant ones are a favorable
alternative. Campaigns to reduce antibiotic usage and thus reduce
selective pressure for drug-resistance have succeeded in the
reduction of drug-resistance in some settings [34]. Likewise we
Figure 3. Modeling a vaccine with increased efficacy against drug-resistance determinants for an epidemic pathogen (seasonal
influenza). a, SIR model with a proportion p of the population as vaccinated susceptibles (1 subscript) and 1{p as unvaccinated susceptibles (0
subscript), who can get infected with either the drug-sensitive (S superscript) or –resistant (R superscript) strains, get treated (T superscript) or not
(U superscript) and are removed due to recovery or death (Z). This is the model of Ref. [2], modified to include vaccination. b, Model evaluations for
final cumulative proportion resistant among all infections over the course of one season, as a function of the additional vaccine efficacy h against
resistant, compared to sensitive strains (x-axis) and the fraction of influenza infections treated (y-axis). Here, vaccine coverage is 40% and VE =59%.
doi:10.1371/journal.pone.0068940.g003
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show that the use of a vaccine targeting resistant strains can
combat the selective pressure for drug-resistance.
Mechanistically, a key concept is that the presence of drug-
sensitive, competing strains enhances the herd immunity effects of
the vaccine against the resistant strain [50] and allows large
population-level effects despite low efficacy. Such competition has
been documented for strains of S. aureus [51,52] and S. pneumoniae
(for which the best evidence of competition is the existence of
serotype replacement following serotype-specific vaccines [53]); for
influenza, competition results from the immunity to influenza
reinfection that occurs within a season [54]. In the presence of
competition between sensitive and resistant strains, the resistance
vaccine alone does not have to bring the reproductive number
below 1 to lead to elimination of the resistant strain, as for classical
vaccines against monomorphic pathogens [55] but only below that
of its competitor, the sensitive strain.
Vaccine designs for drug-resistant pathogens should take into
account the notion that even a weakly effective vaccine may create
enough of a competitive disadvantage for drug-resistant strains to
facilitate the sensitive strains in outcompeting them population-
wide, despite substantial antimicrobial use. While vaccine design
and approval processes may typically reject the notion of weakly
effective vaccines, we show here that their use as an ecological
intervention against drug-resistance in the population can be
profound. Further, the deployment of such a vaccine at high
coverage rates is not unimaginable, as it could be combined into
routine childhood vaccinations.
Supporting Information
Figure S1 In addition to a vaccine that reduces susceptibility to
acquisition (shown in Main Text Figure 2B), for comparison we
considered vaccine that works via accelerated clearance (as
possibly expected for T-cell-mediated immunity) of S. aureus.
Contour plot of equilibrium stability conditions as a function of
vaccine coverage (p) and specific vaccine efficacy against resistant
strain (VER), for 3 fitness costs. Stability conditions for the
resistant-only and sensitive-only equilibrium were obtained
analytically and were mutually exclusive. The stable equilibrium
state is plotted by color as a function of fitness cost (different
panels), vaccine efficacy against the resistant strain (x-axis) and
vaccine coverage (y-axis).
(TIF)
Figure S2 In order to test a broader range of parameters as
some of parameter values (particularly treatment rate and duration
of infection) are not well understood for S. aureus, we varied the
treatment rate (from 10–100% of MSSA-active antibiotic
prescriptions per person per week) and the clearance rate (from
175–700 days, consistent with range of durations reported in
studies of drug-sensitive or resistant S. aureus carriage in the nose
and throat [56,57]). Here, we used the reduced susceptibility
vaccine and a range of fitness costs, 2% (a), 4% (b), and 8% (c).
(TIF)
Figure S3 Ability of a resistance vaccine against influenza to
counteract the spread of a resistant strain due to an intrinsic fitness
advantage, not due to antimicrobial use. Here the total proportion
resistant over a season is plotted as a function of the additional
vaccine efficacy against the resistant strain h and the intrinsic
fitness advantage of the resistant strain, estimated at about 2% for
the influenza A/H1N1 strain carrying the H275Y neuraminidase
mutation in 2006–9 [46].
(TIF)
File S1 Supporting Methods.
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